Fas/FasL expression has recently been described in varied human malignancies, including hepatocellular carcinoma, lung cancer, colon carcinoma, and astrocytoma where its targeting may reduce tumor-infiltrating lymphocytes production [25]. Here, FASLG is linked to neoplasm.